AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02372266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Maternal-Newborn Infant Discharge
Description: Discharge from the hospital between 12-24 hours of life
Study NCT02372266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine discharge
Description: Discharge of the mother and newborn 2 to 3 days after delivery
Study NCT01561703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
Study NCT01547780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PBR28 and Positron Emission Tomography (PET)
Description: Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
Study NCT00464490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
Study NCT00247611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeWindows Intervention Sessions
Description: At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
Study NCT00247611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
Study NCT01350544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Advocacy
Description: Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
Study NCT00135421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Study NCT02153840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSORI-CM01（YXBCM01） granule
Study NCT03188042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rtACS Stimulation
Description: Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
Study NCT03188042 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
Study NCT00925938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
Study NCT00925938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00521300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
Study NCT00521300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct surgery for acromegaly
Description: Direct transsphenoidal surgery
Study NCT02153840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02153840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04486560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651
Description: ERBE 1.1mm flexible single-use cryoprobe with oversheath
Study NCT01719757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Description: Twice daily
Study NCT01947270 — intervention group
Intervention type: OTHER
Intervention:  Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)
Description: The multidisciplinary intervention program include:~* Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~* Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis
Study NCT00603590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
Study NCT00603590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: Inactive tablet Once a day Identical in appearance to intervention drug
Study NCT03603067 — intervention group
Intervention type: PROCEDURE
Intervention: Ocular surgery
Description: Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
Study NCT04674943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
Study NCT05813821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship in surgery
Description: Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment >7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team.
Study NCT04214080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neurodevelopmental treatment (NDT)
Description: NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
Study NCT04214080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT)
Description: NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
Study NCT04214080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding and oral-motor intervention strategies
Description: Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
Study NCT04214080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding and oral-motor intervention strategies
Description: Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
Study NCT04214080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck and trunk stabilization exercises
Description: Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
Study NCT00876031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trofosfamide, idarubicin, etoposide
Description: oral maintenance therapy for 6 months
Study NCT02057042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-assisted computerized CBT
Description: Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
Study NCT03815890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses 240 mg flat dose
Study NCT03815890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: single dose ipilimumab (1mg/kg) at day 1
Study NCT03815890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: two courses ipilimumab (1mg/kg) at day 1 and 21
Study NCT02757105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEKINDA
Study NCT02757105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03205774 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: 6 hours fasting and free oral intake of water
Description: Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
Study NCT04057820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eat, Sleep, Console (ESC) care tool
Description: The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
Study NCT04235868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell-derived derived pleiotropic factor
Description: After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.
Study NCT04235868 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fibroblast growth factor
Description: After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
Study NCT02057042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
Study NCT00137839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT04581460 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
Study NCT02201108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Pharmaceutical form:film-coated tablet, Route of administration: oral
Study NCT02201108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:tablet, Route of administration: oral
Study NCT00235170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: Cypher Sirolimus-eluting Coronary stent
Study NCT04507880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Total Shoulder Arthroplasty
Description: The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
Study NCT04507880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: The shoulder hemiarthroplasty
Study NCT02871882 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Emptying test
Description: participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
Study NCT02871882 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Gastric Emptying test
Description: participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
Study NCT02871882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Oral Glucose Tolerance test
Description: Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
Study NCT02871882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Oral Glucose Tolerance test
Description: Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
Study NCT02871882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated bile acids sodium
Description: 500 mg tablets taken orally twice daily for 28 (+/- 4) days
Study NCT02871882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally twice daily for 28 (+/- 4) days
Study NCT02694432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GOALS
Description: 16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
Study NCT02694432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GOALS
Description: 16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
Study NCT02694432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minding GOALS
Description: 16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
Study NCT00208546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21Capecitabine + bevacizumab + oxaliplatin
Description: 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
Study NCT00208546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab
Description: 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
Study NCT01405066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radiation Dose Audit Reports
Description: Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
Study NCT03923296 — intervention group
Intervention type: DEVICE
Intervention: Blood measurement and monitoring
Description: Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.
Study NCT03923296 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Focus group interviews
Study NCT04461925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells
Description: i/v infusions
Study NCT01405066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Seminar: Radiation Dose Reduction
Description: Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
Study NCT02996643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Assisted Group
Description: A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
Study NCT00266851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 600 mg x 3 days, then 600 mg weekly x 11 weeks
Study NCT00266851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: 600 mg x 3 days, then 600 mg weekly x 11 weeks
Study NCT00266851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00853268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled-Release Oxycodone Hydrochloride 40 mg
Description: Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
Study NCT00853268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyContin® 40 mg tablet
Description: OxyContin® 40 mg tablet, single dose with food
Study NCT06177574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/FTC/TAF
Description: TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
Study NCT01486043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
Study NCT01288976 — intervention group
Intervention type: DEVICE
Intervention: MitraClip
Description: The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
Study NCT01288976 — intervention group
Intervention type: DRUG
Intervention: Medical Management
Description: The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
Study NCT01288976 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral Valve Surgery
Description: The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
Study NCT01122394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TI
Description: Tailored intervention based on the transtheoretical model
Study NCT01122394 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AP
Description: Attention placebo
Study NCT00817687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: As prescribed; + early biopsy
Study NCT00817687 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: mycophenolate mofetil [CellCept]
Description: As prescribed; + standard treatment
Study NCT00039871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks